A second clinical failure means that Biogen threw away $877m, but this sum will today be seen as little more than a rounding error.
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
Data will soon show whether Avadel’s FT218 is more convenient than Jazz’s Xyrem, while Axovant will be looking for a dose response with its Parkinson’s gene therapy.
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
As Meiragtx wows investors with its gene therapy for a cause of blindness, continuing lack of clarity around Gensight’s GS010 prompts more questions than answers.
Biogen’s $877m buyout of Nightstar Therapeutics provides yet more evidence that gene therapy is reaching critical mass.
Promising retinitis pigmentosa results have given Reneuron a boost, but the company still faces a pivotal trial.